hsa-miR-130b-3p Predicts Poor Prognosis Across Renal Cell Carcinoma Subtypes via CD8⁺T Cell Depletion: A Multi-Omics and Clinical Validation StudyImmune Evasion
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Renal cell carcinoma (RCC) is an aggressive genitourinary malignancy comprising three major subtypes: clear cell (KIRC), chromophobe (KICH), and papillary (KIRP). MicroRNAs (miRNAs) orchestrate renal cell carcinoma (RCC) progression, yet pan-subtype biomarkers remain elusive.
Methods
Hsa-miR-130b-3p was upregulated in all subtypes (log₂FC=1.65,FDR=1.07×10⁻⁵ in GSE16441), correlating with poor OS (HR=1.56-2.38, p<0.05) and reduced CD8+ T cell infiltration (r=-0.32, p=0.01). Functional enrichment linked it to mTOR/HIF-1 signaling.
Results
Hsa-miR-130b-3p was upregulated in all subtypes (log₂FC=1.65, FDR=1.07×10⁻⁵ in GSE16441), correlating with poor OS (HR=1.56-2.38, p<0.05) and reduced CD8+ T cell infiltration (r=-0.32, p=0.01). Functional enrichment linked it to mTOR/HIF-1 signaling.
Conclusion
hsa-miR-130b-3p emerges as a simple yet powerful predictor of RCC progression and prognosis, warranting further clinical validation. As a pan-subtype biomarker (3-year AUC=0.82), hsa-miR-130b-3p may facilitate RCC immune evasion, warranting liquid biopsy validation.
This study fills a gap in non-clear cell RCC (KICH/KIRP) by identifying hsa-miR-130b-3p as the first pan-subtype miRNA biomarker (3-year AUC=0.82, p<0.001), validated in 894 TCGA samples and 34 GSE16441 clinical cases. (See Figure 1 for the Graphical Abstract.)
Figure 1Graphical Abstract
